RP501 represents an extension into the medical technology arena for Redwood Pharma
Redwood Pharma extends its reach into the medical technology arena with the broadening of its development programs with the RP501 for dry eye treatment. With its roots in pharmaceutical development, RP501 is an extension into medical devices building upon the latest clinical data from the company. Redwood is now devising the best strategy to commercialize this new treatment initially in Europe.Facts about the medical technology industry in Europe[1] · 33,000 medical technology companies in Europe · 95% are small and medium-sized companies (SME) (i.e. Redwood Pharma) · Most